HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Persistent exudative retinal detachment after photodynamic therapy and intravitreal bevacizumab injection for multiple retinal capillary hemangiomas in a patient with von Hippel-Lindau disease.

Abstract
Photodynamic therapy (PDT) has been used in treating peripheral retinal capillary hemangioma (RCH) with satisfactory results. We report a rare case of von Hippel-Lindau (VHL) disease with three large peripheral RCHs, treated with PDT and intravitreal bevacizumab injection (IVB), who developed persistent bullous exudative retinal detachment (RD) despite significant tumor regression. The patient is a sporadic case of VHL disease, with a de novo nonsense mutation in codon 161 with C → T transition at nucleotide position 694 of the VHL gene. Multiple RCHs were noted in both eyes. Four small RCHs were found in the left eye and were treated with laser photocoagulation. Three large RCHs in the peripheral retina of the right eye were complicated with cystoid macular edema and subretinal fluid accumulation. The RCHs were treated with PDT combined with IVB, and bullous exudative RD developed on the second day after treatment. Three months after PDT, the tumors had regressed significantly, but exudative RD persisted, despite multiple IVB and intravitreal triamcinolone acetonide injection (IVTA). External drainage with sclera buckling, IVB, and IVTA were performed, and the retina attached after surgical intervention. The application of PDT in the treatment of RCHs and its possible complications are discussed.
AuthorsFang-Yi Tsai, Ling-Ing Lau, Shih-Jen Chen, Fenq-Lih Lee, Shui-Mei Lee
JournalJournal of the Chinese Medical Association : JCMA (J Chin Med Assoc) Vol. 77 Issue 1 Pg. 52-6 (Jan 2014) ISSN: 1728-7731 [Electronic] Netherlands
PMID24206762 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright © 2013. Published by Elsevier B.V.
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
Topics
  • Angiogenesis Inhibitors (administration & dosage, adverse effects)
  • Antibodies, Monoclonal, Humanized (administration & dosage, adverse effects)
  • Bevacizumab
  • Female
  • Hemangioma, Capillary (drug therapy)
  • Humans
  • Intravitreal Injections
  • Photochemotherapy (adverse effects)
  • Retinal Detachment (chemically induced)
  • Retinal Neoplasms (drug therapy)
  • Young Adult
  • von Hippel-Lindau Disease (complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: